Literature DB >> 16009537

Hepatotoxicity associated with the use of a fixed combination of chloroquine and proguanil.

R Wielgo-Polanin1, L Lagarce, E Gautron, B Diquet, P Lainé-Cessac.   

Abstract

Here we report on a case of hepatotoxicity associated with the use of a fixed combination of chloroquine and proguanil. Alternative causes of liver injury were excluded. The pathophysiological mechanism remains unclear, with a possibility of allergic reaction. In view of the widespread use of both drugs, clinicians should be aware of this drug-induced liver injury.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16009537     DOI： 10.1016/j.ijantimicag.2005.04.019

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  7 in total

1.  Concurrent Inflammation Augments Antimalarial Drugs-Induced Liver Injury in Rats.

Authors:  Hossein Niknahad; Reza Heidari; Roya Firuzi; Farzaneh Abazari; Maral Ramezani; Negar Azarpira; Massood Hosseinzadeh; Asma Najibi; Arastoo Saeedi
Journal:  Adv Pharm Bull       Date:  2016-12-22

Review 2.  Practical guidelines for diagnosis and early management of drug-induced liver injury.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

3.  Atovaquone/proguanil-induced autoimmune-like hepatitis.

Authors:  Benedetta Terziroli Beretta-Piccoli; Giorgina Mieli-Vergani; Raffaela Bertoli; Luca Mazzucchelli; Charity Nofziger; Markus Paulmichl; Diego Vergani
Journal:  Hepatol Commun       Date:  2017-05-08

Review 4.  Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity.

Authors:  Siya Kamat; Madhuree Kumari
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

Review 5.  Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies.

Authors:  Mohammad Mehdi Ommati; Ali Mobasheri; Reza Heidari
Journal:  J Biochem Mol Toxicol       Date:  2021-05-11       Impact factor: 3.568

6.  Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions.

Authors:  Stephen J Balevic; Shruti M Raja; Rachel Randell; Gregory A Deye; Thomas Conrad; Aya Nakamura; David H Peyton; Sandra Shotwell; Katherine Liebman; Michael Cohen-Wolkowiez; Jeffrey T Guptill
Journal:  Infect Dis Ther       Date:  2022-02-20

Review 7.  New concepts in antimalarial use and mode of action in dermatology.

Authors:  Sunil Kalia; Jan P Dutz
Journal:  Dermatol Ther       Date:  2007 Jul-Aug       Impact factor: 2.851
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.